Oscar Patterson-Lomba
Education
Ph.D., applied mathematics, Arizona State University; B.S., physics, Montclair State University
Summary of Experience
Dr. Patterson-Lomba has broad experience using mathematical epidemiology and statistical approaches to address a wide range of health care research challenges. His expertise includes comparative efficacy and safety, indirect mixed-treatment comparisons, dynamic transmission models, predictive analytics, burden of illness, and individualized medicine, as well as designing and implementing analytics platforms to enhance research capabilities. Dr. Patterson-Lomba has applied statistical methodologies to study clinical and economic outcomes in a broad range of disease areas, including infectious diseases, oncology, psychiatry, immunology, and ophthalmology, and has experience using a variety of data sources, including clinical trials, administrative claims, medical charts, surveys, and medical literature. His research has also involved using complex dynamic models of infectious diseases to assess the cost effectiveness of interventions such as treatment, vaccination, and non-pharmacological strategies. His work has been published in peer-reviewed journals and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Patterson-Lomba was a postdoctoral fellow in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health.
-
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause
Menopause, 2024
2024Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, Siddiqui E, Kagan R
-
Structured Literature Review to Identify Human Papillomavirus's Natural History Parameters for Dynamic Population Models of Vaccine Impacts
Infectious Diseases and Therapy, 2024
2024Diakite I, Martins B, Owusu-Edusei K, Palmer C, Patterson-Lomba O, Gomez-Lievano A, Zion A, Simpson R, Daniels V, Elbasha E
-
Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons
Therapeutic Advances in Neurological Disorders, 2024
2024Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M
-
Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13-15 in the US: projections from an age-structured vaccination model
Frontiers in Pediatrics, 2024
2024Saxena K, Patterson-Lomba O, Gomez-Lievano A, Zion A, Cunningham-Erves J, Kepka D
-
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States
Neurology and Therapy, 2023
2023Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K
-
Comparative Efficacy and Safety of Ozanimod and Ponesimod for Relapsing Multiple Sclerosis: A Matching-Adjusted Indirect Comparison
Multiple Sclerosis and Related Disorders, 2023
2023Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K
-
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom
Vaccine, 2022
2022Daniels V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, Saah A, Luxembourg A, Velicer C, Chen YT, Elbasha E
-
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Development of the PREDS Score to Predict in-Hospital Mortality of Patients with Ebola Virus Disease under Advanced Supportive Care: Results from the EVISTA Cohort in the Democratic Republic of the Congo
eClinicalMedicine, 2022
2022Jaspard M, Mulangu S, Juchet S, Serra B, Dicko I, Lang HJ, Baka BM, Komanda GM, Katsavara JM, Kabuni P, Mambu FM, Isnard M, Vanhecke C, Letord A, Dieye I, Patterson-Lomba O, Mbaya OT, Isekusu F, Mangala D, Biampata JL, Kitenge R, Kinda M, Anglaret X, Muyembe JJ, Kojan R, Ezzedine K, Malvy D
-
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review
Current Medical Research and Opinion, 2021
2021Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba C, Wang Y, King S, Levinson W, Guérin A, Lefebvre P, Davis LL
-
Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States
Current Medical Research and Opinion, 2021
2021Saxena K, Marden JR, Carias C, Bhatti A, Patterson-Lomba O, Gomez-Lievano A, Yao L, Chen YT
-
Estimating the drivers of urban economic complexity and their connection to economic performance
Royal Society Open Science, 2021
2021Gomez-Lievano A, Patterson-Lomba O
-
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J
-
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J
-
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer
Breast Journal, 2019
2019Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA
-
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer
Current Oncology, 2019
2019Levy BP, J E Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M
-
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis
Clinical Therapeutics. Apr 2018;40(4):628-639 e623
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA
-
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
2018 Oct;35(10):1564-1577
2018Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL
-
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Current Medical Research and Opinion. 2018 Sep;34(9):1645-1652
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA